Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Touyun Biotech Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 0.
Touyun Biotech Group's Days Inventory for the
six
months ended in Dec. 2025 was 124.68.
Touyun Biotech Group's Days Payable for the
six
months ended in Dec. 2025 was 51.11.
Therefore, Touyun Biotech Group's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 73.57.
Touyun Biotech Group (HKSE:01332) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Touyun Biotech Group Cash Conversion Cycle Related Terms
Touyun Biotech Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Touyun Biotech Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01332 vs SW, PKG, IP: Cash Conversion Cycle Comparison
For the Packaging & Containers subindustry, Touyun Biotech Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Touyun Biotech Group Cash Conversion Cycle vs Packaging & Containers Industry
For the Packaging & Containers industry and Consumer Cyclical sector, Touyun Biotech Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Touyun Biotech Group's Cash Conversion Cycle falls into.
Touyun Biotech Group Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Touyun Biotech Group's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Touyun Biotech Group (HKSE:01332) has a Cash Conversion Cycle of 73.57 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Touyun Biotech Group and its competitors.
Is Touyun Biotech Group's Cash Conversion Cycle too high?
Touyun Biotech Group's current Cash Conversion Cycle is 73.57. The Packaging & Containers industry median Cash Conversion Cycle is 87.68. Touyun Biotech Group's value of 73.57 is 16.1% below this industry median. Overall, Touyun Biotech Group has a GF Score™ of 25/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Touyun Biotech Group's Cash Conversion Cycle compare to SW and PKG?
Touyun Biotech Group's Cash Conversion Cycle of 73.57 can be compared against companies in the Packaging & Containers industry. The industry median Cash Conversion Cycle is 87.68. Touyun Biotech Group's value of 73.57 is 16.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Packaging & Containers company?
The median Cash Conversion Cycle among Packaging & Containers companies is 87.68, based on 395 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Touyun Biotech Group's current Cash Conversion Cycle of 73.57 is 16.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Touyun Biotech Group and its competitors. For the Packaging & Containers industry, the median Cash Conversion Cycle is 87.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Touyun Biotech Group's current Cash Conversion Cycle is 73.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Touyun Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, Touyun Biotech Group (HKSE:01332) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.16, compared to a current price of HK$0.14 — trading 13.1% below its estimated fair value. The current Cash Conversion Cycle is 73.57 and 16.1% below the Packaging & Containers industry median of 87.68. Touyun Biotech Group's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Touyun Biotech Group (HKSE:01332), the current Cash Conversion Cycle is 73.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Touyun Biotech Group (HKSE:01332) Overvalued in 2026?
Based on GuruFocus' analysis, Touyun Biotech Group stock appears to be undervalued.
The current stock price of HK$0.14 is trading 13.1% below its estimated GF Value™ of HK$0.16.
GuruFocus considers Touyun Biotech Group to be Modestly Undervalued.
Key valuation signals for HKSE:01332:
Cash Conversion Cycle: 73.57
GF Value™: HK$0.16 vs. price of HK$0.14 (13.1% below fair value)
Industry Position: 16.1% below the Packaging & Containers median
No single metric tells the full story. See the HKSE:01332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Touyun Biotech Group Ltd is principally engaged in the (i) the manufacture and sale of packaging products; (ii) investments and trading in securities and money lending, and (iii) production and sale of Chlamydomonas reinhardtii, micro-algae and related products. The company generates majority of its revenue from packaging products segment.
25GF Score
Get the complete analysis for HKSE:01332
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01332 has been successfully added to your 
